Recent research sheds light on how changes in the chemical structure of a protein called Interleukin-6 affect lung cancer’s ...

A new study presented at ESCMID Global 2025 highlights interleukin-6 (IL-6) as a fast, accurate biomarker for early sepsis ...

Biologics targeting interleukin (IL)-12, IL-23, and IL-17 may have valuable safety benefits among older adults with psoriatic disease, as a lower rate of serious infection was observed among these ...

Chronic spontaneous urticaria is chronic inflammatory skin disease driven in part by type 2 inflammation, which causes sudden ...

T helper 17 (Th17) cells generate the pro-inflammatory cytokine interleukin-17 (IL17/IL17A). IL17 has been a target for a variety of therapeutic monoclonal antibodies and inhibitors to treat ...

Department of Medicine, University of Toronto, Women's College Hospital, and co-authors have found biologics targeting interleukin (IL)-12, IL-23, or IL-17 were associated with a lower rate of ...

A study presented at ESCMID Global 2025 has uncovered the potential of interleukin-6 (IL-6) as a powerful diagnostic ...

Interleukin 1 (IL-1) is a 17 kDa protein highly conserved through evolution and is a key mediator of inflammation, fever and the acute-phase response. IL-1 has important functions in the innate ...

Background: Interleukin-17A (IL-17A) is the founding member of a novel family of inflammatory cytokines that plays a critical role in the pathogenesis of many autoimmune diseases, including ...

This is a developing news story. Please check back soon for updates. Tremfya reduced signs and symptoms of psoriatic ...

Biologics targeting interleukin (IL)-12, IL-23, or IL-17 are linked to a 35% lower rate of serious infections in older adults with psoriatic disease compared to other treatments.